Acquisition - February 25, 2020
AstraZeneca divests global rights to Movantik to RedHill Biopharma
AstraZeneca has agreed to sublicense its global rights to Movantik (naloxegol), excluding Europe, Canada and Israel, to RedHill Biopharma (RedHill). Movantik is a peripherally acting mu-opioid receptor antagonist (PAMORA) indicated for the treatment of opioid-induced constipation (OIC). “This divestment supports our strategy to realise value from medicines in our portfolio that are mature or outside our current scope […]
Acquisition - August 26, 2015
Recipharm signs agreement with RedHill Biopharma
Recipharm has announces that it has signed an agreement with Israeli biopharmaceutical company RedHill Biopharma for the manufacturing of RedHill’s leading, late-stage patented drug candidate, RHB-105. RHB-105 is being developed for the treatment of Helicobacter pylori (H. pylori) bacterial infection, a global market estimated at about $4.8 billion. Recipharm will be responsible for the supply […]
